caladrius Developing Innovative Therapies that Treat or Reverse Disease David J. Mazzo, PhD President & Chief Executive Officer M ay 5 , 2 0 22| N a s d a q : C L B S 2 Information regarding disclosures Forward-Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this com ...

Call Start: 16:30 January 1, 0000 5:07 PM ET Caladrius Biosciences, Inc. (CLBS) Q1 2022 Earnings Conference Call May 5, 2022 16:30 ET Company Participants John Menditto - Vice President of Investor Relations & Corporate Communications David Mazzo - President & Chief Executive Officer James Nisco - Vice President of Finance & Treasury Kristen Buck - Chief Medical Officer Conference Call Participants Kumar Raja - Brookline Capital Markets Emanuela Branchetti - H.C. Wainwright Pete Enderlin - MAZ Partners Oper ...

Caladrius Biosciences, Inc. (CLBS) Q4 2021 Earnings Conference Call March 22, 2022 4:30 PM ET Company Participants John Menditto – Vice President-Investor Relations and Corporate Communications David Mazzo – President and Chief Executive Officer James Nisco – Vice President-Finance and Treasury Kristen Buck – Executive Vice President-Research and Development and Chief Medical Officer Conference Call Participants Kumar Raja – Brookline Capital Markets Lander Ron – H.C. Wainwright Pete Enderlin – MAZ Partners ...

Caladrius Biosciences, Inc. (CLBS) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants John Menditto - Vice President-Investor Relations and Corporate Communications David Mazzo - President and Chief Executive Officer Kristen Buck - Executive Vice President of R&D and Chief Medical Officer James Nisco - Vice President-Finance and Treasury Conference Call Participants Kumaraguru Raja - Brookline Capital Markets Emanuela Branchetti - H.C. Wainwright Peter Enderlin - MAZ Partners ...

Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update August 5, 2021 Conference call begins today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a corporate update and reports financial results for the three and six months ended ...

Caladrius Biosciences, Inc. (CLBS) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants John Menditto – Vice President-Investor Relations and Corporate Communications David Mazzo – President and Chief Executive Officer James Nisco – Vice President-Finance and Treasury Conference Call Participants Sara Nik – H.C. Wainwright Shubhendu Sen Roy – Brookline Pete Enderlin – MAZ Partners Operator Welcome to the Caladrius Biosciences Second Quarter 2021 Financial Results and Business Upda ...

Caladrius Biosciences, Inc. (CLBS) Q1 2021 Results Earnings Conference Call May 6, 2021 4:30 PM ET Company Participants John Menditto - Vice President, Investor Relations and Corporate Communications David Mazzo - President and Chief Executive Officer James Nisco - Vice President, Finance and Treasury Conference Call Participants Pete Enderlin - MAZ Partners Operator Welcome to the Caladrius Biosciences First Quarter 2021 Financial Results and Business Update Conference Call. [Operator Instructions] As a re ...

caladrius Developing Regenerative Therapies that Reverse Chronic Disease David J. Mazzo, PhD President & Chief Executive Officer February 25, 2021 | Nasdaq: CLBS Forward-looking statement 2 This Investor Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this presentation, and involve certain risks and uncertainties. All statements other than state ...

Caladrius Biosciences, Inc. (CLBS) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants John Menditto - Vice President, Investor Relations and Corporate Communications David Mazzo - President and Chief Executive Officer Conference Call Participants Emanuela Branchetti - H.C. Wainwright Pete Enderlin - MAZ Partners Operator Welcome to the Caladrius Biosciences Fourth Quarter and Year End 2020 Financial Results and Business Update Conference Call. [Operator Instructions] As a rem ...

caladrius Developing Regenerative Therapies that Reverse Chronic Disease David J. Mazzo, PhD President & Chief Executive Officer January 19, 2021 | Nasdaq: CLBS Forward-looking statement 2 This Investor Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this presentation, and involve certain risks and uncertainties. All statements other than statem ...